Vivakor, Inc. quarterly report, Q1 FY2009

Vivakor, Inc. 10-Q Summary: Quarter Ended March 31, 2009

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Vivakor, Inc., a trans-disciplinary biomedical company incorporated in Nevada. The report covers the three-month period ended March 31, 2009. The Company focuses on the discovery, development, and commercialization of medical devices and pharmaceuticals, as well as contract research services. As of the reporting date, the Company had 50,660,660 shares of common stock outstanding.

Key Financial Metrics

MetricQ1 2009Q1 2008
Total Revenue$6,223$50,000
Net Loss$(505,237)$7,430 (Income)
Net Loss Attributable to Vivakor$(500,246)$7,430
Operating Expenses$445,428$42,570
Cash and Cash Equivalents (End of Period)$20,990$33,042
Total Current Liabilities$2,461,739$2,410,617
Stockholders' Equity (Deficit)$(111,667)$293,570

Debt and Liquidity: The Company holds a significant note payable of $1,387,774 related to the acquisition of HealthAmerica, Inc. Additionally, there are $353,486 in loans and advances from related parties. Cash flow from operating activities was negative $116,679 for the quarter.

Material Changes vs. Prior Period

  • Revenue Shift: Revenue dropped from $50,000 in Q1 2008 (research services) to $6,223 in Q1 2009 (product sales of Cryovials). Research revenue was zero in the current period.
  • Expense Surge: Operating expenses increased nearly tenfold to $445,428, driven primarily by a rise in Research and Development (R&D) costs from $4,059 to $297,121. This increase includes $185,485 in amortization of patents acquired in late 2008.
  • One-Time Charges: The Company recorded a $111,316 charge for abandoned offering costs after terminating a capital formation activity (Form S-1) in April 2009.
  • Profitability: The Company swung from a net income of $7,430 in the prior year to a net loss of $505,237.

Outlook, Risks, and Management Commentary

Going Concern: Management and the independent auditors have expressed substantial doubt regarding the Company's ability to continue as a going concern. The Company does not have sufficient cash to fund operations for the next twelve months and relies on obtaining additional financing through debt, equity, or strategic partnerships.

Capital Formation Failure: A planned public offering of 15,000,000 shares was terminated in April 2009 after failing to receive payment for subscriptions. Consequently, $111,316 in deferred offering costs were expensed.

Debt Default: The Company is in default on its $1,387,774 note payable, having failed to make required monthly payments of $25,000. The note holder, an entity controlled by a shareholder, has not taken enforcement action as of the filing date.

Subsequent Event: On May 5, 2009, the Company was awarded a $112,912 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

Investor Verification Checklist

  • Liquidity Crisis: Verify the Company's ability to secure immediate funding given cash reserves of only $20,990 and a negative operating cash flow.
  • Debt Status: Confirm the status of the $1.39M note payable default and whether the related-party lender has initiated any collection actions.
  • Revenue Sustainability: Assess the viability of the new product sales (Cryovials) which generated only $6,223 in revenue, compared to the previous reliance on contract research.
  • Grant Contingencies: Review the terms of the $152,455 grant payable, which may become due if the Company moves out of Iowa or sells a majority of assets.
  • Related Party Transactions: Scrutinize the $353,486 in loans from related parties and the conversion of $100,000 of debt into equity.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.